Squadron Capital Management LLC
CIK: 0002050709Latest portfolio: $236.0M · Q4 2025
Holdings
33
Total Value
$236.0M
New Positions
33
Closed Positions
0
Top Holdings
View All 33 Holdings →| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | RLMDRELMADA THERAPEUTICS INC | 6,700,000 | $32.4M | 13.71% | |
| 2 | COGTCOGENT BIOSCIENCES INC | 780,000 | $27.7M | 11.74% | |
| 3 | MAZEMAZE THERAPEUTICS INC | 490,000 | $20.3M | 8.60% | |
| 4 | ABVXABIVAX SA | 145,000 | $19.6M | 8.29% | |
| 5 | KALVKALVISTA PHARMACEUTICALS INC | 700,000 | $11.3M | 4.79% | |
| 6 | PALIPALISADE BIO INC | 4,500,000 | $10.6M | 4.48% | |
| 7 | EWTXEDGEWISE THERAPEUTICS INC | 350,000 | $8.7M | 3.68% | |
| 8 | IKTINHIBIKASE THERAPEUTICS INC | 4,225,000 | $8.7M | 3.67% | |
| 9 | KODKODIAK SCIENCES INC | 291,710 | $8.2M | 3.46% | |
| 10 | TERNTERNS PHARMACEUTICALS INC | 190,000 | $7.7M | 3.25% | |
| 11 | AVBPARRIVENT BIOPHARMA INC | 338,000 | $6.8M | 2.88% | Call |
| 12 | TARSTARSUS PHARMACEUTICALS INC | 80,000 | $6.5M | 2.78% | |
| 13 | UPBUPSTREAM BIO INC | 230,650 | $6.3M | 2.65% | |
| 14 | SPRBSPRUCE BIOSCIENCES INC | 70,000 | $6.1M | 2.58% | |
| 15 | XENEXENON PHARMACEUTICALS INC | 105,551 | $4.7M | 2.00% | |
| 16 | DBVTDBV TECHNOLOGIES S A | 240,000 | $4.6M | 1.95% | |
| 17 | HELPCYBIN INC | 525,000 | $4.3M | 1.82% | |
| 18 | LPCNLIPOCINE INC NEW | 530,000 | $4.3M | 1.80% | |
| 19 | BLTEBELITE BIO INC | 26,000 | $4.2M | 1.76% | |
| 20 | GHRSGH RESEARCH PLC | 315,000 | $4.0M | 1.70% | |
| 21 | EPRXEUPRAXIA PHARMACEUTICALS INC | 500,000 | $3.8M | 1.60% | |
| 22 | VTYXVENTYX BIOSCIENCES INC | 410,000 | $3.7M | 1.57% | |
| 23 | NXTCNEXTCURE INC | 236,966 | $3.4M | 1.42% | |
| 24 | VERAVERA THERAPEUTICS INC | 60,000 | $3.0M | 1.29% | Call |
| 25 | WVEWAVE LIFE SCIENCES LTD | 175,000 | $3.0M | 1.26% |
Sector Breakdown
Healthcare100.0% ($3.236127705203002e+125T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $236.0M | 33 |
Fund Information
Squadron Capital Management LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $236.0M across 33 holdings. The largest position is RELMADA THERAPEUTICS INC (RLMD), representing 13.7% of the portfolio. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.